BioCryst Pharmaceuticals, Inc.
(NASDAQ : BCRX)

( )
BCRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.08%196.181.2%$557.67m
TSROTESARO, Inc.
0.22%74.2514.4%$534.38m
CELGCelgene Corporation
1.18%69.491.2%$528.88m
GILDGilead Sciences, Inc.
0.34%67.720.9%$508.18m
BIIBBiogen Inc.
0.11%319.791.3%$358.06m
ILMNIllumina, Inc.
1.81%328.903.5%$353.03m
REGNRegeneron Pharmaceuticals, Inc.
-0.50%375.722.6%$262.39m
AAgilent Technologies, Inc.
0.67%71.061.5%$237.22m
VRTXVertex Pharmaceuticals Incorporated
-0.32%173.231.9%$235.67m
ALXNAlexion Pharmaceuticals, Inc.
0.16%114.832.0%$143.36m
SRPTSarepta Therapeutics, Inc.
1.79%125.0015.4%$112.54m
INCYIncyte Corporation
0.28%65.602.5%$104.06m
EXASExact Sciences Corporation
-0.04%69.5225.3%$99.67m
NKTRNektar Therapeutics
-0.63%36.435.5%$97.21m
EXELExelixis, Inc.
-1.78%20.986.4%$82.17m

Company Profile

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema. The company was founded in 1986 and is headquartered in Durham, NC.